Literature DB >> 14966048

Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK.

S Stewart1, N F Murphy, N Murphy, A Walker, A McGuire, J J V McMurray.   

Abstract

OBJECTIVE: To evaluate the cost of atrial fibrillation (AF) to health and social services in the UK in 1995 and, based on epidemiological trends, to project this estimate to 2000. DESIGN, SETTING, AND MAIN OUTCOME MEASURES: Contemporary estimates of health care activity related to AF were applied to the whole population of the UK on an age and sex specific basis for the year 1995. The activities considered (and costs calculated) were hospital admissions, outpatient consultations, general practice consultations, and drug treatment (including the cost of monitoring anticoagulant treatment). By adjusting for the progressive aging of the British population and related increases in hospital admissions, the cost of AF was also projected to the year 2000.
RESULTS: There were 534 000 people with AF in the UK during 1995. The "direct" cost of health care for these patients was 244 million pounds sterling (approximately 350 million euros) or 0.62% of total National Health Service (NHS) expenditure. Hospitalisations and drug prescriptions accounted for 50% and 20% of this expenditure, respectively. Long term nursing home care after hospital admission cost an additional 46.4 million pounds sterling (approximately 66 million euros). The direct cost of AF rose to 459 million pounds sterling (approximately 655 million euros) in 2000, equivalent to 0.97% of total NHS expenditure based on 1995 figures. Nursing home costs rose to 111 million pounds sterling (approximately 160 million euros).
CONCLUSIONS: AF is an extremely costly public health problem.

Entities:  

Mesh:

Year:  2004        PMID: 14966048      PMCID: PMC1768125          DOI: 10.1136/hrt.2002.008748

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  26 in total

1.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G de Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

2.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

Authors:  Simon Stewart; Carole L Hart; David J Hole; John J V McMurray
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

3.  Malignant hypertension. Declining mortality rate in New York City, 1958 to 1974.

Authors:  T H Lee; M H Alderman
Journal:  N Y State J Med       Date:  1978-08

4.  Trends in case-fatality in 22968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995.

Authors:  S Stewart; K MacIntyre; J W T Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; S Capewell; J J V McMurray
Journal:  Int J Cardiol       Date:  2002-03       Impact factor: 4.164

5.  The current cost of heart failure to the National Health Service in the UK.

Authors:  Simon Stewart; Andrew Jenkins; Scot Buchan; Alistair McGuire; Simon Capewell; John J J V McMurray
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

6.  Prevalence of coronary heart disease in Scotland: Scottish Heart Health Study.

Authors:  W C Smith; M B Kenicer; H Tunstall-Pedoe; E C Clark; I K Crombie
Journal:  Br Heart J       Date:  1990-11

7.  Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database.

Authors:  A Majeed; K Moser; K Carroll
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

8.  Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study.

Authors:  S Capewell; K MacIntyre; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

9.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.

Authors:  S Stewart; C L Hart; D J Hole; J J McMurray
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

10.  The current cost of angina pectoris to the National Health Service in the UK.

Authors:  S Stewart; N F Murphy; N Murphy; A Walker; A McGuire; J J V McMurray
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

View more
  141 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

2.  Atrial fibrillation: an emerging epidemic?

Authors:  J S Steinberg
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

3.  Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?

Authors:  Stanley Nattel
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

4.  Pharmacological rhythm and rate control treatment for atrial fibrillation: patient and physician satisfaction.

Authors:  Nils Edvardsson; Anders Westlund; Margareta Thimell; Karin Rise; Alexander Todoran; Tanja Aberg Kurén; John Kindblom; Olle Almgren
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

5.  Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation. A prospective randomised 1-year implantable cardiac monitoring device follow-up trial.

Authors:  S J Podd; A N Sulke; C Sugihara; S S Furniss
Journal:  J Interv Card Electrophysiol       Date:  2015-08-27       Impact factor: 1.900

Review 6.  Antithrombotic treatment in atrial fibrillation.

Authors:  G Y H Lip; C J Boos
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 7.  Identification, diagnosis and assessment of atrial fibrillation.

Authors:  R I Dewar; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

8.  Anticoagulation for stroke prevention: high effectiveness, more cost benefit?

Authors:  Eduard Shantsila; Timothy Watson; Gregory Y H Lip
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Warfarin: almost 60 years old and still causing problems.

Authors:  Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

10.  Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Authors:  Kostas Athanasakis; Eleftheria Karampli; Dimitrios Tsounis; Aikaterini Bilitou; John Kyriopoulos
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.